Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2015 | Results for the follow-up of the RESPONSE study

Jean-Jacques Kiladjian • 2 Jun 2015
ASCO 2015
Myeloproliferative Neoplasms Ruxolitinib

Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.

More from Jean-Jacques Kiladjian

Preliminary results from trials targeting mutant CALR for the treatment of MPNs 1:16
Preliminary results from trials targeting mutant CALR for the treatment of MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The disease-modifying potential of CALR-targeted therapies in MPNs 0:55
The disease-modifying potential of CALR-targeted therapies in MPNs
Jean-Jacques Kiladjian • 13 Jun 2025
The management of MPNs in young patients: transitioning from pediatric to adult care 1:57
The management of MPNs in young patients: transitioning from pediatric to adult care
Jean-Jacques Kiladjian • 13 Jun 2025
MPN Sessions: Key updates from EHA 2022
Claire Harrison et al. • 12 Jun 2022

Related Videos

Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms 1:39
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll • 7 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals